The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Hepatotoxicity of Chemotherapy
Abstract
After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,900
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients
Pratt, D. S., & Kaplan, M. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004273421707 · Cited by 1,203
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
A clinical review of bleomycin—a new antineoplastic agent
Blum, R. H., Carter, S. K., & Agre, K. (1973) · Cancer · doi:10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n · Cited by 864
KEMENY, N., DALY, J., REICHMAN, B., GELLER, N., BOTET, J., & ODERMAN, P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-459 · Cited by 649
Clinical toxicity of interferons in cancer patients: a review.
Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 596
Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
ELLISON, R. R., HOLLAND, J. F., WEIL, M., JACQUILLAT, C., BOIRON, M., BERNARD, J., SAWITSKY, A., ROSNER, F., GUSSOFF, B., SILVER, R. T., et al. (1968) · Blood · doi:10.1182/blood.v32.4.507.507 · Cited by 549
Cancer chemotherapy and biotherapy: Principles and practice
Ellis, L. E. (1997) · Surgical Oncology · doi:10.1016/s0960-7404(97)00005-4 · Cited by 418
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chabner, B. A., & Longo, D. L. (1996) · Cited by 409
Cited by
Karoui, M., Penna, C., Amin-Hashem, M., Mitry, E., Benoist, S., Franc, B., Rougier, P., & Nordlinger, B. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000193603.26265.c3 · Cited by 721
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Sp1 transcription factor: A long-standing target in cancer chemotherapy
Vizcaíno, C., Mansilla, S., & Portugal, J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.008 · Cited by 377
Clinical Biochemistry of Hepatotoxicity
P Sharma, O. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.s4-001 · Cited by 305
Hepatotoxicity of Chemotherapy
Floyd, J., Mirza, I., Sachs, B., & Perry, M. C. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.11.002 · Cited by 279
Self-citation
Metadata
- Authors
- King, P. D., & Perry, M. C.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04-01
- Volume
- 6
- Issue
- 2
- Pages
- 162-176
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2140279988
- Cited by
- 454
- References
- 83
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity of Chemotherapy. https://app.cochat.ai/papers/10.1634/theoncologist.6-2-162
- The paper
- King, P. D., & Perry, M. C. (2001). Hepatotoxicity of Chemotherapy. The Oncologist. https://doi.org/10.1634/theoncologist.6-2-162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
